Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Organicell Regenerative Medicine Inc BPSR


Primary Symbol: OCEL

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of biological therapeutics for the treatment of degenerative diseases and to provide other related services. RAAM products are used in the healthcare industry administered through doctors and clinics. Its leading product, Zofin (Organicell Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. The product contains over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs as well as other exosomes derived from perinatal tissues. It has obtained certain Investigation New Drug (IND), and emergency IND (eIND) approvals from the United States Food and Drug Administration (FDA), including applicable Institutional Review Board (IRB) approvals which authorized the Company to commence clinical trials.


OTCQB:OCEL - Post by User

Post by indaknownewfieon Apr 29, 2021 9:29pm
210 Views
Post# 33099017

Reposted from stocktwits

Reposted from stocktwitsWhere am I wrong here? Short term = $1 - $1.50 Indian EUA for Covid = $3 - $5 US EUA for Covid = $8 - $12 US approval/COPD = $12 - $15 US approval-OA = $20 Indian EUA is just days/weeks away. FDA knows the heat will be coming as to why they’ve had this in their lap since May 2020 and haven’t approved it, prompting Approval or Congressional hearings. And remember the key factor regarding Zofin and Covid.... Aviptadil ‘may’ get an EUA sooner, but was only trialed for severe Covid. Zofin is moderate to severe. So, a patient with risk factors of reaching severe Covid will get Zofin, not Aviptadil. If at-risk patients get Zofin, few if any ever reach the severe stage of Covid. Long haulers have already been treated with Zofin and have shown dramatic results long after Covid was gone (most have seen the news clip on this) COPD is next, then Osteoarthritis. Zofin is NOT a one-hit wonder! Do your DD and see for yourself!
<< Previous
Bullboard Posts
Next >>